Stock Pick of the Week (4/6)
Overview
Merck Pharmaceuticals (MRK) is a global pharmaceutical giant specializing in oncology, vaccines, and treatments for infectious diseases. Simply put, Merck is the "engine and immune system" of modern medicine. While companies like hospitals and insurers manage healthcare delivery, Merck develops the blockbuster drugs and vaccines that actually treat and prevent disease — most notably Keytruda, the world's best-selling cancer drug.
Comparison
Merck (Green) vs. Eli Lilly (Blue)
A big name in the pharmaceutical space is Eli Lilly (LLY), whose stock has surged on the back of its GLP-1 weight-loss drugs. While Lilly has dominated the metabolic disease conversation, Merck's diversified pipeline across oncology and vaccines makes it a more balanced play on long-term healthcare growth. Trading at a reasonable valuation relative to peers, MRK offers a compelling entry point for investors who missed the LLY run-up.
Why Pharmaceuticals
Healthcare is one of the most recession-resistant sectors on the market; people need medicine regardless of economic conditions. As the global population ages, demand for cancer treatments, vaccines, and chronic disease therapies is only accelerating. Pharmaceutical companies with dominant, patent-protected drugs generate predictable, high-margin cash flows that fund both R&D and shareholder returns. Merck checks every box: oncology dominance through Keytruda, a strong acquisition strategy actively building its future pipeline beyond Keytruda's patent cliff, and a very strong dividend safety profile that rewards patient investors. With analysts projecting roughly 10% EPS growth next year, Merck combines the stability of a healthcare giant with the upside of a growth story.
Why-to-Buy
As Keytruda continues to expand into new cancer indications, Merck's pipeline matures, and the broader pharmaceutical sector benefits from aging demographics, the company's core business should remain resilient. Supported by a reasonable valuation, double-digit earnings growth on the horizon, and a rock-solid dividend, MRK is CFR's pick of the week!